Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSLER-2 open-label extension of AMG 145
NL-OMON45229Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Aug 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of evolocumab in dyslipidemia, hypercholesterolemia and familial hypercholesterolemia (FH), sponsored by Amgen. Primary endpoint: Adverse events. Started Aug 2013; status: active, not recruiting.
02
Drugs
evolocumab
03
Conditions
dyslipidemiahypercholesterolemiafamilial hypercholesterolemia (FH)
Beyond the preview
Go deeper on NL-OMON45229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45229.